InChI
1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1
SMILES string
CC(C)(S)[C@@H](N)C(O)=O
InChI key
VVNCNSJFMMFHPL-VKHMYHEASA-N
grade
pharmaceutical primary standard
API family
penicillamine
manufacturer/tradename
EDQM
mp
210 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Penicillamine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 2
Mona S El Raziky et al.
Journal of pediatric hematology/oncology, 36(3), 173-178 (2014-03-01)
Wilson disease (WD) is an inherited disorder of copper metabolism. Hemolytic anemia in WD occurs in up to 17% of patients at some point during their illness. To screen for WD among children presenting with hemolytic anemia. Twenty cases (mean
S L Klingenberg et al.
The Cochrane database of systematic reviews, (1)(1), CD004182-CD004182 (2006-01-27)
Primary sclerosing cholangitis is a cholestatic disease. D-penicillamine is suggested as a treatment option due to its copper reducing and immunomodulatory potential. To evaluate the beneficial and harmful effects of D-penicillamine for patients with primary sclerosing cholangitis. Eligible trials were
[D-penicillamine nephropathy].
I Ohno
Ryoikibetsu shokogun shirizu, (16 Pt 1)(16 Pt 1), 523-525 (1997-01-01)
A Boehler et al.
The European respiratory journal, 9(6), 1317-1319 (1996-06-01)
D-penicillamine-associated bronchiolitis obliterans (BO) is a rare but well-known pulmonary complication in patients with rheumatoid arthritis or progressive systemic sclerosis. It has been assumed that in most, if not all cases, BO is a complication of the underlying disease rather
Y Gong et al.
Alimentary pharmacology & therapeutics, 24(11-12), 1535-1544 (2007-01-09)
D-Penicillamine is used for patients with primary biliary cirrhosis due to its ability to decrease hepatic copper and modulate the immune response. The results on effects of D--penicillamine in randomized-clinical trials of primary biliary cirrhosis patients are inconsistent. To systematically
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持